No exacerbations and no dyspnea/low COPD impact (ie, mMRC 0 to 1 or CAT <10)¶ | |
Current therapy | Actions |
SABA or SABA-SAMA as needed | Continue current therapy |
LAMA, LABA, or LAMA-LABA | Continue current therapy |
LABA-ICS or LABA-LAMA-ICS | Taper or discontinue ICS dose to reduce adverse effects of ICSΔ |
Persistent dyspnea or high COPD impact (ie, mMRC ≥2 or CAT ≥10)¶ with no exacerbations | |
Current therapy | Actions |
SABA or SABA-SAMA as needed | Add LAMA or LABA |
LAMA or LABA monotherapy | Change to LAMA-LABA |
LABA-ICS |
|
LAMA-LABA |
|
LAMA-LABA-ICS |
|
1 or more exacerbations in past year +/– persistent dyspnea or high COPD impact (ie, mMRC ≥2 or CAT ≥10)¶ | |
Current therapy§ | Actions |
SABA or SABA-SAMA as needed | Add LAMA |
LAMA or LABA monotherapy |
|
LAMA-LABA |
|
LABA-ICS |
|
LAMA-LABA-ICS |
|
COPD: chronic obstructive pulmonary disease; mMRC: modified Medical Research Council; CAT: COPD Assessment Test; SABA: short-acting beta-agonist; SAMA: short-acting muscarinic-antagonist; LAMA: long-acting muscarinic-antagonist; LABA: long-acting beta-agonist; ICS: inhaled corticosteroids (glucocorticoids); BMI: body mass index; SpO2: pulse oxygen saturation; FEV1: forced expiratory volume in one second.
* Adjustments to pharmacologic therapy for COPD are based on an assessment of dyspnea/exercise limitation (mMRC or CAT), frequency of exacerbations, and peripheral blood eosinophil counts. Follow-up visits are also an opportunity to assess and reinforce nonpharmacologic interventions for COPD, including: smoking cessation; inhaler technique and adherence to medications; administration of pneumococcal and seasonal influenza vaccinations; pulmonary rehabilitation; and nutrition counselling regarding healthy diet and normal BMI. All patients with COPD should have a rapid relief inhaler available, either a SABA or a SABA-SAMA (SABA preferred for patients using a LAMA). Refer to UpToDate content on the overview of management for stable COPD.
¶ mMRC dyspnea scale: https://www.pcrs-uk.org/mrc-dyspnoea-scale; CAT evaluates health impact of COPD: https://www.catestonline.org.
Δ If blood eosinophil count ≥300 cells/microL, patient is more likely to experience exacerbations after ICS withdrawal. Close patient monitoring is required if ICS are withdrawn.
◊ In patients with exacerbations and blood eosinophil count ≥300 cells/microL, the addition of ICS is likely to be of benefit. For patients with eosinophil counts ≥100 but <300 cells/microL, ICS may improve exacerbation rates and pulmonary function.
§ Nonpharmacologic measures (eg, oxygen therapy if SpO2 ≤88%, pulmonary rehabilitation, bronchoscopic or surgical lung volume reduction, lung transplantation) can help reduce dyspnea and exacerbations. Contributing comorbidities should be evaluated and treated. Not all patients achieve control of dyspnea or exacerbations despite optimal available pharmacotherapy.
¥ For patients with a blood eosinophil count <100 cells/microL, there is a low likelihood that addition of ICS will be beneficial and higher risk of pneumonia after the addition of ICS.
‡ Roflumilast is used for patients with chronic bronchitis and FEV1 <50% predicted, particularly if there has been at least 1 hospitalization for an exacerbation in the past year. Potential adverse effects may limit use.
† Azithromycin preventive therapy is more effective in patients who are not current smokers. However, it may lead to development of resistant organisms.Do you want to add Medilib to your home screen?